{"entity":{"id":"nct05316155","kind":"trial","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","aka":[],"tldr":"A phase 1/2 trial of Erdafitinib in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer is a phase 1/2 interventional study registered as NCT05316155 by Janssen Research & Development, LLC, with 235 participants enrolled, started 2022-04-11 and due to reach its primary completion in 2028-03-30. Interventions recorded: Erdafitinib Intravesical Delivery System.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05316155","url":"https://clinicaltrials.gov/study/NCT05316155"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["erdafitinib"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05316155","phase":"1/2","setting":"Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer","sponsor":"Janssen Research & Development, LLC","enrolled":235,"outcomes":[]},"route":"/trials/nct05316155/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}